Clinical Trial Update: A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating subcutaneous versus intravenous administration of blinatumomab in newly diagnosed adults with Philadelphia chromosome-negative B-c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-negative B-cell Precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (Blincyto) (blinatumomab)

Snippet

Sponsor: Amgen | Conditions: Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Status: NOT_YET_RECRUITING